Combination therapies exploring simultaneous inhibition of RET and the related pathways will provide insight into the clinical utility of such strategies, indeed several investigators have already started trials of combined therapy for patients with advanced MTC as well as other thyroid cancers. This evidence concerns the gene RET and medullary thyroid gland carcinoma.